El Prof. Merimsky dirige la Unidad de Oncología de Tejidos Blandos y Huesos del Centro Médico Sourasky, con más de 25 años de experiencia especializada en el tratamiento del timoma.
El Dr. Yuri Goldes es cirujano general con más de 20 años de experiencia clínica. Se especializa en cirugía gastrointestinal alta y oncológica. Es subdirector del Departamento de Cirugía General y Trasplante del Centro Médico Sheba en Tel Aviv y dirige la Unidad de Cirugía Gastrointestinal Alta. En 2025 fue incluido en la lista de los Mejores Médicos de Forbes Israel. Está entre los mejores cirujanos gastrointestinales de Israel según Forbes. En 2019 recibió el premio “Médico del Año” del Ministerio de Salud de Israel.
Es experto en cirugía avanzada mínimamente invasiva y robótica. Trata hernia diafragmática, acalasia, enfermedad por reflujo gastroesofágico (ERGE) y patología de la vesícula biliar. También realiza cirugía oncológica para cánceres de páncreas, estómago y esófago. Utiliza técnicas laparoscópicas y robóticas.
Fue pionero de algunas de las primeras resecciones oncológicas robóticas de estómago y páncreas en Israel. Forma parte de un pequeño grupo a nivel mundial que realiza procedimientos de Whipple (pancreatoduodenectomía) mínimamente invasivos mediante laparoscopia avanzada. Aplica métodos que mejoran los resultados y aceleran la recuperación. Brinda atención personalizada.
El Dr. Ari Raphael dirige la investigación genómica del timoma en el Centro Médico Sourasky, siendo pionero en técnicas de biopsia líquida.
El profesor Raanan Berger, MD, PhD, es oncólogo médico y radioterapeuta. Es director del Centro Oncológico del Sheba Medical Center y dirige su unidad de investigación clínica. Fue incluido en la lista “Best Doctors” de Forbes Israel (2025). Lidera el programa de oncología genitourinaria, con enfoque en el cáncer de próstata. Su práctica incluye terapia sistémica y radioterapia en un modelo multidisciplinario centrado en el paciente.
Es especialista en oncología. Obtuvo los títulos de MD y PhD en la Universidad de Tel Aviv y completó su formación clínica en Sheba. Posteriormente realizó una beca posdoctoral en Dana-Farber/Harvard, centrada en cáncer de próstata con el Dr. Philip Kantoff y en oncología molecular en el laboratorio del Dr. William C. Hahn. Es miembro de ESMO y ASCO. Es coautor de más de 20 artículos revisados por pares, entre ellos estudios sobre resultados en cáncer de próstata de alto frente a muy alto riesgo y sobre BRCA1/2 en grandes cohortes.
Recommended hospitals in Israel for thymoma treatment include Sourasky Medical Center, Sheba Medical Center, and Assuta Medical Center. These JCI-accredited facilities offer specialized multidisciplinary thoracic oncology programs. Leading specialists like Dr. Ofer Merimsky provide genomics-driven care and advanced minimally invasive surgical resections for complex mediastinal tumors.
Bookimed Expert Insight: Israeli medical centers often separate thoracic surgery from general cardiac departments. Sheba Medical Center performs hundreds of complex mediastinal procedures annually. Sourasky Medical Center reports a 90% average success rate for oncology. This specialization ensures patients receive care from surgeons dedicated specifically to the chest and thymus.
Patient Consensus: Patients emphasize the importance of choosing centers that co-manage myasthenia gravis alongside thymoma. Many note that English-speaking staff at major centers significantly simplifies the treatment process.
Surgical options in Israel include minimally invasive VATS, robotic-assisted thymectomy, and open sternotomy for advanced cases. JCI-accredited centers like Sourasky Medical Center and Assuta utilize Da Vinci robotic systems. These technologies allow for precise tumor removal with significantly faster recovery times for oncology patients.
Bookimed Expert Insight: Israeli surgical centers like Rambam and Sourasky operate at massive scales, with Sourasky performing over 34,000 surgeries annually. Data shows these high-volume centers often treat many complex thymoma cases that general hospitals might turn away. Patients should prioritize clinics with integrated research units, as these facilities frequently participate in clinical trials for rare thoracic malignancies.
Patient Consensus: Patients emphasize the importance of getting a PET or CT scan before surgery to see if they qualify for robotic procedures. Many also advise checking for myasthenia gravis symptoms early, as this condition often appears after the thymus gland is removed.
Israel reports high success for thymoma treatment. The 5-year survival rate for patients undergoing surgery for locally advanced tumors is 81%. Early-stage cases treated with radical resection approach 95% to 100% survival. Leading centers like Sourasky Medical Center maintain a 90% average success rate across oncology departments.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center integrate genomic profiling into standard care. Dr. Ari Raphael specializes in these molecular tumor boards. This level of precision allows teams to identify systemic therapies for stage IV patients. This often results in a 40% to 60% 5-year survival rate for advanced cases.
Patient Consensus: Patients emphasize the need for PET-CT scans to ensure the tumor is fully removable before surgery. Many note that choosing robotic approaches led to significantly faster healing and less pain.
Advanced systemic therapies like immunotherapy and targeted agents are available for thymoma treatment in Israel. Centers like Sourasky Medical Center lead international trials for drugs including pembrolizumab. These therapies are typically used for advanced stage 3 or 4 cases after conventional treatments like surgery or chemotherapy.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center report a 90% success rate in oncology treatments. This is partly due to doctors inventing new protocols specifically for thoracic cancers. Patients often visit professors like Ofer Merimsky for specialized surgery and modern drug therapy combined in one facility.
Patient Consensus: Patients note that immunotherapy is rarely a first choice for thymoma due to risks of autoimmune flares. Many emphasize getting PD-L1 testing and myasthenia gravis screening before starting advanced drug protocols at Israeli clinics.
During an initial consultation for thymoma in Israel, discuss staging accuracy and screening for myasthenia gravis. Patients should confirm if a multidisciplinary tumor board reviews their case. Inquire about surgical approaches like robotic resection or treatment sequencing involving chemotherapy for borderline resectable tumors.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center report survival rates around 90%. Patients should capitalize on the specialized expertise of doctors like Dr. Ari Raphael. He leads a Molecular Tumor Board and interprets complex genomic profiling. This level of detail is crucial for rare thoracic malignancies where standard protocols may need adjustment.
Patient Consensus: Patients often emphasize the need to record the consultation and verify staging details. They note it is important to bring a written list of questions covering fertility preservation and potential complications.